Leon Kircik, MD discusses the potential role of emerging AD treatments, including:

• Why has atopic dermatitis lagged behind compared to psoriasis in terms of approved targeted treatments?
• What are some of the most promising therapies that will likely be part of the AD treatment table in the near future?
• Do you foresee that they will be also approved for pediatric AD, or only for the adult population?
• In terms of assessing disease severity, how practical are the scales used in clinical trials? Should we put more emphasis on patient-reported outcomes?